# Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity

> **NCT07508306** · — · RECRUITING · sponsor: **Faculty of Medicine of Tunis** · enrollment: 30 (estimated)

## Conditions studied

- Sentinel Lymph Node Biopsy (SLNB)
- Early Stage Ovarian Tumors

## Interventions

- **PROCEDURE:** Sentinel node biopsy with patent blue dye

## Key facts

- **NCT ID:** NCT07508306
- **Lead sponsor:** Faculty of Medicine of Tunis
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-02-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07508306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07508306, "Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07508306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*